Drug intelligence / Profile preview

iloprost + nitric oxide

Development stage
Phase 4
Lead developer
Bayer
Modality
Small Molecules
Administration
Inhalation, Intravenous
01

Overview

Iloprost + nitric oxide is a combination of two vasodilators used primarily in the management of pulmonary arterial hypertension (PAH) and acute pulmonary hypertension. Iloprost is a synthetic analogue of prostacyclin (PGI2), which acts as a potent vasodilator by mimicking endogenous prostacyclin to relax vascular smooth muscle and inhibit platelet aggregation. Nitric oxide (NO), administered as an inhaled gas, induces vasodilation by stimulating guanylate cyclase in vascular smooth muscle cells to increase cyclic GMP levels. Both agents lower pulmonary vascular resistance through distinct intracellular pathways—iloprost via cAMP and NO via cGMP—and are sometimes used together for additive or alternative effects in patients with PAH or during cardiac surgery. However, studies indicate that their combination does not provide significantly greater hemodynamic benefit than either agent alone[1][2][4][5].

Brand names
Ilomedin
Other names
prostacyclin analog + inhaled nitric oxidePGI2 analog + iNO
02

Targets

PTGIR (Prostanoid IP Receptor)sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on iloprost + nitric oxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on iloprost + nitric oxide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call